HIV RRE Binding Compounds Disrupting Rev Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-HIV drugs target viral proteins rather than viral RNAs, lacking an effective approach to inhibit the nuclear export of unspliced and singly spliced HIV RNA, which relies on the interaction between the viral protein Rev and the Rev response element (RRE) RNA.
Innovation Solution
Development of compounds that bind to the HIV RRE RNA, specifically inhibiting the binding of Rev to the RRE by linking two moieties that target the two Rev binding sites with a spacing of about 30-80 Å, including peptides and small organic molecules like aminoglycoside antibiotics, which can also include detectable labels or cargo moieties for therapeutic and diagnostic purposes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed to bind to two Rev binding sites simultaneously, then binding affinity and inhibition efficacy are improved, but molecular complexity and synthesis difficulty increase
Solution Approach 1:
The compound is divided into two distinct moieties (first moiety and second moiety), each capable of independently binding to one of the two Rev binding sites on RRE. This segmentation allows each moiety to be optimized for its specific binding site while maintaining overall function, resolving the contradiction between achieving high binding affinity and managing molecular complexity
Solution Approach 2:
A linker serves as an intermediary component connecting the first and second moieties. This linker mediates the spatial relationship between the two binding sites, allowing the compound to simultaneously engage both Rev binding sites while maintaining a manageable molecular structure through controlled flexibility and spacing
2Reliability
If the spacing between binding moieties is optimized for simultaneous binding, then inhibition efficacy improves, but manufacturing precision requirements increase
Solution Approach 1:
The linker providing spacing between the two moieties is designed to be flexible rather than rigid, allowing dynamic adjustment of the distance and orientation between binding moieties. This flexibility enables the compound to adapt to the spatial arrangement of Rev binding sites on RRE, achieving effective inhibition without requiring extremely precise manufacturing tolerances for the spacing
3Measurement precision
If detectable labels are incorporated into RRE binders, then detection sensitivity improves, but background noise and false positives may increase
Solution Approach 1:
The detectable label is incorporated locally into specific RRE binder molecules rather than universally, allowing differentiation between specifically bound labeled binders and background noise. This localized incorporation strategy enables sensitive detection of HIV-infected cells while managing background interference through spatial and temporal discrimination
Data Source
AI summary
Compounds (such as peptides or peptide mimetics) that bind to HIV RRE RNA are provided. In some examples, the compounds inhibit (for example, decrease) binding of Rev to the RRE RNA. In some embodiments, the compounds include two moieties, each of which bind to one of the Rev binding sites in the RRE. In some examples, the moieties include peptides or small molecules. In some examples, the peptides include an arginine-rich motif. The RRE binding compounds may be further linked to a detectable label or cargo moiety. Also provided are methods of treating or inhibiting HIV including administering one or more of the RRE binding compounds to a subject.